Where Debate & Discussion Translate to Treatment

Save $50 on registration. Use code GDUGI
gioncologydebates.com

New York, NY
April 2–4
New 3-Day Format

Chicago, IL
September 25–26

Los Angeles, CA
October 23–24
Interested in Exhibiting?

This conference series offers several support opportunities that are designed to increase your companies' recognition and the opportunity to showcase your products and services to this audience of oncology professionals.

678.242.0719
exhibits@imedex.com

Compelling Arguments.
Engaging Discussions.
Practical Takeaways.
Known for its unique, debate-style format, thought leaders from the nation’s leading cancer institutes meet onstage to dive into the most controversial topics shaking up the field of gastrointestinal cancer:

- Colorectal Cancers
- Emerging Concepts and Therapies in GI
- Hepatobiliary Cancers
- Immunotherapy
- Pancreatic Cancers
- Rare Tumors
- Upper GI Cancers

Meet the Chairs

Axel Grothey, MD
West Cancer Center
Memphis, Tennessee

David H. Ilson, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, New York

ENDORSEMENT
The following organization endorses this conference:

[Community Oncology Alliance logo]
SCIENTIFIC AGENDA

Day 1 | New York, Chicago, Los Angeles

1:00 PM Welcome and Introduction

Session I: Colorectal Cancers I

1:10 PM Pre-Session Audience Survey
1:20 PM Early-Onset Colorectal Cancer: A Biologically Distinct Threat?
1:40 PM Debate: FOxTROT or Not: Neoadjuvant Therapy for Locally Advanced Colon Cancer
2:00 PM The Nonoperative Management of Rectal Cancer
2:20 PM Post-Session Audience Survey
2:30 PM Expert Panel Discussion
2:50 PM Break

Session II: Colorectal Cancers II

3:20 PM How Similar are Biosimilars?
3:50 PM Debate: First-Line Treatment in Left-Sided, RAS/BRAF WT Cancer EGFR vs VEGF
4:10 PM Debate: First-Line Therapy for BRAF V600E Targeted Triplet vs FOLFOXIRI/Bev
4:30 PM Debate: Are Biomarkers like CMS and ctDNA Ready to Direct Adjuvant Therapy
4:50 PM Debate: High-Risk Stage II Colon Cancer 3 Months of CAPOX vs 6 Months of Capecitabine
5:10 PM Expert Panel Discussion
5:30 PM Adjourn

Day 2 | New York, Chicago, Los Angeles

8:00 AM Welcome and Introduction

Session III: Pancreatic Cancer

8:10 AM Pre-Session Audience Survey
8:20 AM New Treatment Options in Pancreatic Cancer
8:50 AM Debate: Resectable Pancreatic Cancer Total Neoadjuvant Therapy vs Adjuvant Therapy
9:10 AM Debate: Maintenance Therapy in BRCA+ Pancreatic Cancer PARP Inhibitor vs Continued Chemotherapy
9:30 AM Post-Session Audience Survey
9:40 AM Expert Panel Discussion
9:50 AM Break

Session IV: Hepatobiliary Cancers

10:20 AM Pre-Session Audience Survey
10:30 AM Novel and Targeted Therapies in Biliary Cancer
11:00 AM Debate: Optimal First-Line Therapy for HCC VEGF-Targeted Therapy vs Checkpoint Inhibitor
11:20 AM Management of Adverse Events With Immunotherapy
11:40 AM Novel Agents and Targets in HCC
12:10 PM Locoregional Treatment Approaches: When to Use and When Not to Use
12:30 PM Post-Session Audience Survey
12:40 PM Expert Panel Discussion

SCIENTIFIC AGENDA

12:50 PM  Lunch

Session V: Targeted Approaches in Gastric Cancers and Other GI Malignancies

1:50 PM  Pre-Session Audience Survey
2:00 PM  Current Positioning of Immunotherapy in Gastroesophageal Cancer
2:20 PM  Novel Non-Immunotherapy Targets and Agents in Gastroesophageal Cancer
2:40 PM  Novel Agents and Targets in Colorectal Cancer
3:10 PM  Debate: TNT for Rectal Cancer
          Short-Course Radiation Therapy vs Long-Course Radiation Therapy
3:30 PM  Debate: Comprehensive Molecular Panel Testing in GI Cancers
          A Waste of Resources vs Mandatory for All Metastatic GI Cancers
3:50 PM  Post-Session Audience Survey
4:00 PM  Break

Session VI: Gastroesophageal Cancer

4:30 PM  Debate: Ablative Therapies for Oligometastatic Disease Fact vs Fiction
4:50 PM  Debate: Esophageal and GEJ Cancers CROSS vs FLOT
5:10 PM  Debate: Adjuvant Therapy in Biliary Cancers: Capecitabine Standard Therapy
5:30 PM  Adjourn

Day 3 | New York Only*

8:00 AM  Welcome and Introduction

Session VII: Gastrointestinal Cancer: Emerging Concepts and Therapies

8:10 AM  Genetics in GI Cancers
8:30 AM  Circulating Tumor DNA: Emerging Role in Adjuvant and Advanced Disease Therapy
9:00 AM  Molecular Tumor Board: Case Presentations on Clinical Implications of Next-Generation Sequencing in Different Tumor Types
9:30 AM  Expert Panel Discussion
9:50 AM  Break

Session VIII: Rare Tumors

10:20 AM  Novel Agents and Approaches in NETs
10:50 AM  Debate: SURFs Up: Early HCC Surgery vs Ablative Therapy
11:10 AM  Debate: Optimal Second-Line Therapy in pNET Cape/Tem vs PRRT
11:30 AM  Expert Panel Discussion
12:00 PM  Adjourn

* New York will be the only 3-day series.
The entire agenda will be presented at all locations.
Agenda and Faculty are subject to change. Please visit the website for the latest conference details.
2020 Faculty*

*Includes confirmed and invited speakers.

Ghassan Abou-Alfa, MD
Memorial Sloan Kettering Cancer Center
Weill Cornell Medical College
New York, New York

Axel Grothey, MD
West Cancer Center
Memphis, Tennessee

David H. Ison, MD, PhD
Memorial Sloan Kettering Cancer Center
Weill Cornell Medical College
New York, New York

Scott Kopetz, MD
MD Anderson Cancer Center
University of Texas
Houston, Texas

Geoffrey Y. Ku, MD
Memorial Sloan Kettering Cancer Center
New York, New York

Eileen M. O’Reilly, MD
Memorial Sloan Kettering Cancer Center
Weill Cornell Medical College
New York, New York

Jonathan R. Strosberg, MD
Mohffit Cancer Center
Tampa, Florida

Noam A. Vanderwalde, MD, MS
West Cancer Center
University of Tennessee Health
Memphis, Tennessee

Tanios Bekaii-Saab, MD, FACP
Mayo Clinic
Phoenix, Arizona

Jordan D. Berlin, MD
Vanderbilt Ingram Cancer Center
Vanderbilt University Medical Center
Nashville, Tennessee

Andrea Cercek, MD
Memorial Sloan Kettering Cancer Center
New York, New York

Michael A. Choti, MD
Banner MD Anderson Cancer Center
Gilbert, Arizona

Christopher H. Crane, MD
Memorial Sloan Kettering Cancer Center
New York, New York

Cathy Eng, MD, FACP, FASCO
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee

Julio Garcia-Aguilar, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, New York

Howard S. Hochster, MD
Rutgers Cancer Institute of New Jersey
Robert Wood Johnson School of Medicine
New Brunswick, New Jersey

Diane Reidy Lagunes, MD
Memorial Sloan Kettering Cancer Center
New York, New York

Jeffrey Meyerhardt, MD, MPH, FASCO
Dana-Farber Cancer Institute
Harvard University
Boston, Massachusetts

Rachna Shroff, MD
University of Arizona College of Medicine
Tucson, Arizona

Constantinos T. Sofocleous, MD, PhD
Memorial Sloan Kettering Cancer Center
Weill Cornell Medical College
New York, New York

Zsofia K. Stadler, MD
Memorial Sloan Kettering Cancer Center
New York, New York

Faculty are subject to change. Please visit the website for the latest conference details.

CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Imedex. NACCME is jointly accredited by ACCME, the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Statements:
- Physicians: This activity has been approved for AMA PRA Category 1 Credit(s)™.
- Nurses: This continuing nursing education activity has been approved to offer continuing contact hours for nurse professionals. This activity will also award pharmacotherapeutic contact hours. Final designation of these hours will be provided upon final review of the conference agenda.
- Pharmacy: This live, knowledge-based activity has been approved to offer continuing education units (CEUs) for pharmacists.

Learning Objectives: Upon completion of this activity, participants should be able to:
- Analyze the mechanism of action (MOA) and safety-efficacy profiles of currently approved and emerging oncological agents including immunotherapies for the management of GI malignancies.
- Integrate clinical trial data and evidence-based therapies for improving clinical outcomes in patients with GI malignancies.
- Evaluate the best practices and standards of care based on a multidisciplinary approach for the management of GI cancers.
- Implement the rational use of immunotherapies in patients with GI malignancies on a case-by-case basis.
- Define patient populations most suitable for enrolling in GI clinical trials for progressive advanced-stage GI malignancies.
- Implement optimal management strategies for both metastatic and non-metastatic GI malignancies based on personalized factors such as comorbidities, cost, disease stage, and prior therapeutic regimens.

WHO SHOULD ATTEND

This live educational activity is designed to meet the educational needs of those who are involved and/or interested in the treatment of patients with GI cancers.

Community Oncologists
Physicians
Physician Assistants
Pharmacists

GROUP DISCOUNTS

Available for attendees from the same practice!
More Locations, Education, and Value.

WAYS TO REGISTER
Online: gIOncologydebates.com
Phone: 800.233.0957
International: 678.242.0906
Email: registration@imedex.com

Use code GDUGI to save $50 on registration!

<table>
<thead>
<tr>
<th>REGISTRATION RATES</th>
<th>EARLY</th>
<th>REGULAR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physician/PhD/Pharm</td>
<td>$279</td>
<td>$329</td>
</tr>
<tr>
<td>PA/NP</td>
<td>$169</td>
<td>$199</td>
</tr>
<tr>
<td>Nurse/Student/Resident/Fellow</td>
<td>$89</td>
<td>$99</td>
</tr>
<tr>
<td>Industry</td>
<td>$549</td>
<td>$549</td>
</tr>
</tbody>
</table>

REGISTRATION CUTOFF REMINDERS:
- New York, NY 2/28/20
- Chicago, IL 8/21/20
- Los Angeles, CA 9/10/20

Enroll in the Great Debates & Updates Value Package and save by signing up for multiple locations at once!
Visit the meeting website to book these special event rates.

New York Marriott Marquis
Special Room Rate
$349 per night, plus tax.
1535 Broadway
New York, NY 10036

Chicago Marriott Magnificent Mile
Special Room Rate
$215 per night, plus tax.
540 N Michigan Ave
Chicago, IL 60611

Marina Del Ray Marriott
Special Room Rate
$239 per night, plus tax.
4100 Admiralty Way
Marina del Rey, CA 90292
Where Debate & Discussion Translate to Treatment

NOW OFFERING THREE LOCATIONS

April 2–4, 2020  |  3 Days!
New York, NY

September 25–26, 2020
Chicago, IL

October 23–24, 2020
Los Angeles, CA

Save $50 on registration by using code GDUGI.
gioncologydebates.com